Abstract
Immune checkpoint inhibitors such as Pembrolizumab are used to restore antitumour immune response. It is important to be vigilant of immune mediated adverse events related to such therapy. We report a case of autoimmune limbic encephalitis with Contactin-Associated Protein-like 2 (CASPR2) antibody secondary to Pembrolizumab therapy for metastatic melanoma.
Copyright © 2017 Elsevier B.V. All rights reserved.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Autoantibodies / therapeutic use*
-
Autoimmune Diseases / diagnostic imaging
-
Autoimmune Diseases / immunology*
-
Autoimmune Diseases / therapy*
-
Humans
-
Limbic Encephalitis / diagnostic imaging
-
Limbic Encephalitis / immunology*
-
Limbic Encephalitis / therapy*
-
Magnetic Resonance Imaging
-
Male
-
Melanoma / immunology
-
Melanoma / therapy
-
Membrane Proteins / immunology*
-
Nerve Tissue Proteins / immunology*
Substances
-
Antibodies, Monoclonal, Humanized
-
Autoantibodies
-
CNTNAP2 protein, human
-
Membrane Proteins
-
Nerve Tissue Proteins
-
pembrolizumab
Supplementary concepts
-
Autoimmune limbic encephalitis